Inhibiting SHP2 in macrophages may promote M1 TAM (antitumor phenotype) polarization and create a microenvironment conducive to antitumor immunity, making it a potential target for tumor immunotherapy [35,36]. This evidence concerns the gene PTPN11 and neoplasm.